• Rigel and AstraZeneca have an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled IL-13/IL-4 signaling inhibitor, for chronic asthma.

  • AstraZeneca has exclusive rights to commercialize R256 around the world and, will be responsible for designing and conducting the clinical development of the compound.

  • Rigel has received $15 million in upfront and early milestone payments. Together with other specific developmental, regulatory and launch milestone payments, the collaboration could be worth up to $100 million.

  • In addition, Rigel will be eligible for tiered royalty payments on product sales.